• 1
    Crohn B. Segmental (Granulomatous) colitis. A historical survey. Bibl Gastroenterol. 1970: 8589.
  • 2
    Antonioli DA. Pediatric inflammatory bowel disease. Pediatr Dev Pathol. 2005; 8: 219.
  • 3
    Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology. 2006; 130: 10691077.
  • 4
    Israel EJ, Kleinman RE. Inflammatory bowel disease: diagnosis and treatment. Semin Gastrointest Dis. 1994; 5: 95105.
  • 5
    Wilhelm SM, Taylor JD, Osiecki LL, et al. Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics. Ann Pharmacother. 2006; 40: 18041813.
  • 6
    Nakamura K, Honda K, Mizutani T, et al. Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J Gastroenterol. 2006; 12: 46284635.
  • 7
    Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut. 1997; 40: 443448.
  • 8
    Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000; 119: 11481157.
  • 9
    Ganesan S, Travis SP, Ahmad T, et al. Role of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs. 2002; 3: 12971300.
  • 10
    Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo. by probiotic bacteria. Gut. 2002; 51: 659664.
  • 11
    Grip O, Janciauskiene S, Lindgren S. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflamm Bowel Dis. 2004; 10: 193200.
  • 12
    MacDermott RP, Sanderson IR, Reinecker HC. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 1998; 4: 5467.
  • 13
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340: 13981405.
  • 14
    Sands BE. Why do anti-tumor necrosis factor antibodies work in Crohn's disease? Rev Gastroenterol Disord. 2004; 4(suppl 3): S1017.
  • 15
    Kirman I, Whelan RL, Nielsen OH. Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004; 16: 639641.
  • 16
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323333; quiz, 591.
  • 17
    Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999; 13(suppl 4): 1622; discussion, 38.
  • 18
    Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999; 116: 2228.
  • 19
    Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; 3: CD005112.
  • 20
    Sandborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord. 2005; 5: 1018.
  • 21
    Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 10171024; quiz, 976.
  • 22
    Fukuda Y, Matsui T, Suzuki Y, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J Gastroenterol. 2004; 39: 11581164.
  • 23
    Kusaka T, Fukunaga K, Ohnishi K, et al. Adsorptive monocyte-granulocytapheresis (M-GCAP) for refractory Crohn's disease. J Clin Apher. 2004; 19: 168173.
  • 24
    Ljung T, Thomsen OO, Vatn M, et al. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol. 2007; 42: 221227.
  • 25
    Ménard S, Candalh C, Bambou JC, et al. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut. 2004; 53: 821828.
  • 26
    Valeur N, Engel P, Carbajal N, et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol. 2004; 70: 11761181.
  • 27
    Pena JA, Li SY, Wilson PH, et al. Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis. Appl Environ Microbiol. 2004; 70: 558568.
  • 28
    Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microbiol. 2001; 2: 4353.
  • 29
    Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991; 12: 439447.
  • 30
    Kotarski SF, Savage DC. Models for study of the specificity by which indigenous lactobacilli adhere to murine gastric epithelia. Infect Immun. 1979; 26: 966975.
  • 31
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402408.
  • 32
    Littell RC, Milliken GA, Stroup WW, Wolfinger RD. Analysis of repeated measures data. In: SAS system for mixed models. Cary, NC: SAS Publishing; 1996: 87134.
  • 33
    Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol. 1998; 113: 401406.
  • 34
    Banks C, Bateman A, Payne R, et al. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol. 2003; 199: 2835.
  • 35
    Herfarth H, Goke M, Hellerbrand C, et al. Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int J Colorectal Dis. 2003; 18: 401405.
  • 36
    MacDermott RP. Chemokines in the inflammatory bowel diseases. J Clin Immunol. 1999; 19: 266272.
  • 37
    Frankenberger M, Pforte A, Sternsdorf T, et al. Constitutive nuclear NF-kappa B in cells of the monocyte lineage. Biochem J. 1994; 304(Pt 1): 8794.
  • 38
    Haversen L, Ohlsson BG, Hahn-Zoric M, et al. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol. 2002; 220: 8395.
  • 39
    Ziegler-Heitbrock HW, Sternsdorf T, Liese J, et al. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol. 1993; 151: 69866993.
  • 40
    Chen SL, Lin ST, Tsai TC, et al. ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein. Oncogene. 2007; 26: 4253.
  • 41
    Zerbini LF, Wang Y, Czibere A, et al. NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci U S A. 2004; 101: 1361813623.
  • 42
    Joos S, Rosemann T, Szecsenyi J, et al. Use of complementary and alternative medicine in Germany — a survey of patients with inflammatory bowel disease. BMC Complement Altern Med. 2006; 6: 19.
  • 43
    Markowitz JE, Mamula P, delRosario JF, et al. Patterns of complementary and alternative medicine use in a population of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 599605.
  • 44
    Gionchetti P, Amadini C, Rizzello F, et al. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther. 2002; 16(suppl 4): 1319.
  • 45
    Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003; 124: 12021209.
  • 46
    Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004; 53: 108114.
  • 47
    Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2006; 40: 260263.
  • 48
    Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004; 126: 16201633.
  • 49
    Giaffer MH, Holdsworth CD, Duerden BI. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol. 1991; 35: 238243.
  • 50
    Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004; 53: 685693.
  • 51
    Pena JA, Rogers AB, Ge Z, et al. Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. Infect Immun. 2005; 73: 912920.
  • 52
    Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23: 15671574.
  • 53
    Guandalini S. Use of Lactobacillus-GG in paediatric Crohn's disease. Dig Liver Dis. 2002; 34(suppl 2): S6365.
  • 54
    Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000; 31: 453457.
  • 55
    Szajewska H, Mrukowicz JZ. Use of probiotics in children with acute diarrhea. Paediatr Drugs. 2005; 7: 111122.
  • 56
    Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005; 11: 833839.
  • 57
    Prantera C, Scribano ML. Probiotics and Crohn's disease. Dig Liver Dis. 2002; 34(suppl 2): S6667.
  • 58
    Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002; 51: 405409.
  • 59
    Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004; 4: 5.
  • 60
    Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006; 55: 842847.
  • 61
    Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis. 2007; 13: 135142.
  • 62
    Pena JA, Versalovic J. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol. 2003; 5: 277285.
  • 63
    Wallace TD, Bradley S, Buckley ND, et al. Interactions of lactic acid bacteria with human intestinal epithelial cells: effects on cytokine production. J Food Prot. 2003; 66: 466472.
  • 64
    Pathmakanthan S, Li CK, Cowie J, et al. Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol. 2004; 19: 166173.
  • 65
    Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun. 2006; 343: 6976.
  • 66
    Ewaschuk JB, Walker JW, Diaz H, et al. Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr. 2006; 136: 14831487.
  • 67
    Cantor MJ, Nickerson P, Bernstein CN. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol. 2005; 100: 11341142.
    Direct Link:
  • 68
    Levine A, Karban A, Eliakim R, et al. A polymorphism in the TNF-alpha promoter gene is associated with pediatric onset and colonic location of Crohn's disease. Am J Gastroenterol. 2005; 100: 407413.
    Direct Link:
  • 69
    Waschke KA, Villani AC, Vermeire S, et al. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol. 2005; 100: 11261133.
    Direct Link:
  • 70
    Song Y, Wu KC, Zhang L, et al. Correlation between a gene polymorphism of tumor necrosis factor and inflammatory bowel disease. Chin J Dig Dis. 2005; 6: 170174.
  • 71
    Cho JH. Significant role of genetics in IBD: the NOD2 gene. Rev Gastroenterol Disord. 2003; 3(suppl 1): S1822.
  • 72
    Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411: 603606.
  • 73
    Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006; 314: 14611463.
  • 74
    Libioulle C, Louis E, Hansoul S, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007; 3: e58.
  • 75
    Kmiec Z. Cytokines in inflammatory bowel disease. Arch Immunol Ther Exp (Warsz). 1998; 46: 143155.
  • 76
    Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001; 47: 12971301.
  • 77
    Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol. 2005; 17: 547557.
  • 78
    Agnholt J, Dahlerup JF, Buntzen S, et al. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment Pharmacol Ther. 2003; 17: 703710.
  • 79
    Liu H, Sidiropoulos P, Song G, et al. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol. 2000; 164: 42774285.
  • 80
    Yao J, Mackman N, Edgington TS, et al. Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem. 1997; 272: 1779517801.
  • 81
    Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001; 13: 8594.
  • 82
    Hambleton J, Weinstein SL, Lem L, et al. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc Natl Acad Sci U S A. 1996; 93: 27742778.
  • 83
    Dokter WH, Koopmans SB, Vellenga E. Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-kappa B) which are involved in IL-6 regulation. Leukemia. 1996; 10: 13081316.
  • 84
    Ma W, Gee K, Lim W, et al. Dexamethasone inhibits IL-12p40 production in lipopolysaccharide-stimulated human monocytic cells by down-regulating the activity of c-Jun N-terminal kinase, the activation protein-1, and NF-kappa B transcription factors. J Immunol. 2004; 172: 318330.
  • 85
    Finzer P, Soto U, Delius H, et al. Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells: the role of the chromatin structure and AP-1 composition. Oncogene. 2000; 19: 32353244.
  • 86
    Georganas C, Liu H, Perlman H, et al. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol. 2000; 165: 71997206.
  • 87
    van den Brande J, Hommes DW, Peppelenbosch MP. Infliximab induced T lymphocyte apoptosis in Crohn's disease. J Rheumatol Suppl. 2005; 74: 2630.
  • 88
    Mitsuyama K, Suzuki A, Tomiyasu N, et al. Pro-inflammatory signaling by Jun-N-terminal kinase in inflammatory bowel disease. Int J Mol Med. 2006; 17: 449455.
  • 89
    Waetzig GH, Seegert D, Rosenstiel P, et al. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol. 2002; 168: 53425351.
  • 90
    Aggarwal BB, Shishodia S, Takada Y, et al. TNF blockade: an inflammatory issue. Ernst Schering Res Found Workshop. 2006: 161186.
  • 91
    Reimold AM. TNFalpha as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy. 2002; 1: 377392.
  • 92
    Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005; 115: 178181.
  • 93
    Kim YM, Im JY, Han SH, et al. IFN-gamma up-regulates IL-18 gene expression via IFN consensus sequence-binding protein and activator protein-1 elements in macrophages. J Immunol. 2000; 165: 31983205.
  • 94
    Ludwiczek O, Kaser A, Novick D, et al. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. Eur Cytokine Netw. 2005; 16: 2733.
  • 95
    Shen C, Maerten P, Geboes K, et al. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol. 2005; 115: 250259.
  • 96
    Haase R, Richter K, Pfaffinger G, et al. Yersinia outer protein P suppresses TGF-beta-activated kinase-1 activity to impair innate immune signaling in Yersinia enterocolitica-infected cells. J Immunol. 2005; 175: 82098217.
  • 97
    Meijer LK, Schesser K, Wolf-Watz H, et al. The bacterial protein YopJ abrogates multiple signal transduction pathways that converge on the transcription factor CREB. Cell Microbiol. 2000; 2: 231238.
  • 98
    Kim SO, Sheikh HI, Ha SD, et al. G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppression of TNF production in macrophages. Cell Microbiol. 2006; 8: 19581971.
  • 99
    Madara J. Building an intestine—architectural contributions of commensal bacteria. N Engl J Med. 2004; 351: 16851686.
  • 100
    Lin Y, Versalovic J. Immunoregulation by probiotics. Agro Food Industry Hi-Tech. 2006; 17: 5659.
  • 101
    Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 18051811.
  • 102
    Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004; 38: 298301.